Paediatric medicines development for Duchenne muscular dystrophy: An EU regulatory perspective
{{output}}
BackgroundDuchenne muscular dystrophy (DMD) is a severe muscle disease with an unmet therapeutic need. Despite ongoing research efforts, only a few medicines have achieved marketing authorisation in the EU to date. We present a regulatory science overview summ... ...
